Most women on HRT are on two medications: an estradiol patch (or gel) and oral micronized progesterone. Some are also on a small dose of testosterone. Almost none are on DHEA.

That gap exists less because DHEA isn't useful and more because most providers were never trained to think about it. DHEA — dehydroepiandrosterone — is the adrenal hormone that serves as the precursor to a substantial fraction of a woman's sex hormone production, especially after menopause. By age 70, DHEA-S levels are typically 20% of where they were at age 25. The downstream effect on sex hormone availability is real.

Here's the clinical case for considering DHEA in women's HRT, what the bloodwork shows, and what a typical protocol looks like.

What DHEA actually is.

DHEA is produced primarily by the adrenal glands and is the most abundant circulating steroid hormone in healthy adults. It serves as a precursor — your body converts it into androgens (testosterone, androstenedione) and, downstream, into estrogens.

The conversion happens locally in target tissues — skin, bone, brain, vaginal and vulvar tissue, breast — meaning DHEA's effect depends not just on circulating levels but on the tissue-specific enzymes that convert it.

DHEA-S (the sulfated form) is what's typically measured on bloodwork. It's the stable, long-lived form circulating in plasma. Its level reflects total adrenal output.

Why DHEA crashes with age.

Adrenal DHEA production follows a steep age-related decline that's been documented for decades:

  • Age 20–30: peak DHEA-S, typically 200–400 µg/dL
  • Age 40: roughly 60–70% of peak
  • Age 60: roughly 30% of peak
  • Age 80: roughly 15–20% of peak

This decline is independent of menopause — it begins in your 30s and progresses smoothly. It's one of the most reliable biomarkers of biological aging in humans.

Why this matters for women specifically.

In premenopausal women, the ovaries produce most of the body's estradiol and a substantial fraction of its androgens. After menopause, ovarian production essentially stops — and adrenal DHEA becomes the primary source of sex hormones.

A postmenopausal woman with low DHEA-S has lost two upstream sources of sex hormones simultaneously: ovarian production (from menopause) and adrenal precursors (from age-related DHEA decline). The downstream symptoms — fatigue, low libido, mood flatness, loss of skin elasticity, vaginal-tissue thinning — can be partially DHEA-mediated.

The clean framing
Estradiol replacement gives you back the estrogen you've lost. Progesterone replacement gives you back the progesterone. DHEA replacement gives you back the adrenal substrate that the body uses to make its own sex hormones locally — which matters most in postmenopausal women whose ovaries have stopped.

What the literature actually shows.

DHEA is one of the more studied hormones in adult women's health, and the picture is more nuanced than either the supplement industry or skeptical mainstream medicine paints:

  • Vaginal DHEA (prasterone, brand name Intrarosa) is FDA-approved for moderate-to-severe dyspareunia (painful sex) from GSM. The published trials show comparable efficacy to local vaginal estradiol for symptom relief.
  • Oral DHEA in women with low baseline DHEA-S has shown modest but consistent improvements in libido, bone density, and skin elasticity in published trials.
  • DHEA in women with normal DHEA-S shows essentially no benefit — supplementation only helps women who are actually deficient.

The relevant question isn't "does DHEA work?" but "who has low enough DHEA to benefit?"

What the bloodwork looks like.

DHEA-S is the test. A few useful reference points:

  • Premenopausal woman, mid-30s, healthy: typically 100–300 µg/dL
  • Healthy postmenopausal woman, 60s: typically 30–100 µg/dL
  • Functionally deficient: under 30 µg/dL — often symptomatic

Most labs flag values below the absolute reference range, but "functionally low" usually starts well above that threshold. A 55-year-old woman with DHEA-S of 40 µg/dL is technically "normal" by the lab's reference range but may be meaningfully below where her physiology functions best.

What a DHEA protocol looks like.

Three common forms, each with distinct use cases:

1. Vaginal DHEA (prasterone, 6.5 mg insert). FDA-approved, used nightly. Treats GSM symptoms (dryness, pain, urinary changes) with essentially no systemic absorption. Often the cleanest first-line DHEA option for women whose primary symptoms are local.

2. Oral micronized DHEA (10–25 mg daily). Used for women with low DHEA-S and systemic symptoms (fatigue, low libido, mood, skin). Compounded options at DirectCare AI start at 10 mg and titrate to bloodwork response. Often paired with a small amount of pregnenolone for women whose entire steroid axis is downshifted.

3. Compounded transdermal DHEA cream (5–10 mg/day). Used for women who don't tolerate oral DHEA well. Less common, but useful for the right patient.

What to expect on a DHEA protocol.

Typical timeline:

  • Weeks 2–4: DHEA-S levels start to rise. Subjective changes (energy, libido, mood) are subtle in the first month.
  • Weeks 6–8: First lab recheck. Most patients land in the 100–200 µg/dL range. Subjective improvements are usually clearer by now.
  • Months 3–6: Stable maintenance. Bone density effects (if applicable) become measurable around 6–12 months.

What to avoid.

  • Over-the-counter DHEA at high doses (50–100 mg). Sold widely; usually too high a dose for women. The clinical doses we use are almost always under 25 mg.
  • DHEA without bloodwork. Without a DHEA-S level, you don't know if you're deficient. Most women under 45 have plenty.
  • DHEA as a standalone HRT. It works best as part of a complete protocol — estradiol, progesterone, sometimes testosterone, sometimes DHEA. Solo DHEA in a perimenopausal woman is rarely the right call.

The bottom line.

DHEA is the third sex hormone most women's HRT protocols skip. The case for including it is strongest in women over 50 whose DHEA-S is functionally low and who have symptoms — fatigue, libido changes, GSM, mood flatness — that aren't fully resolving on estradiol and progesterone alone.

Pair this with the broader HRT picture in HRT after 40, the GSM case in vaginal estradiol for GSM, and the female libido + testosterone conversation that often runs in parallel.

Most women's HRT protocols are two hormones. The patients who feel best are often on three — sometimes four. DHEA is the one most providers forget to test for.

Sources: Endocrine Society DHEA position statement; Cochrane review on DHEA in postmenopausal women; FDA prescribing information for vaginal prasterone.

Get the complete picture

Hormone therapy that includes all three.

DirectCare AI prescribes estradiol, progesterone, low-dose testosterone, and — when warranted — DHEA, with dosing tuned to your bloodwork by a US-licensed clinician.

Start your HRT consult →

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.